cas 121219-03-2|| where to buy 4-Bromo-3-fluorophenol

Nom du produit:4-Bromo-3-fluorophenol

IUPAC Name:4-bromo-3-fluorophenol

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM117046-1000g	in stock	ƻȷǕſ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 121219-03-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:121219-03-2; Formule moléculaire:C6H4BrFO; Point de fusion:-; Code SMILES:OC1=CC=C(Br)C(F)=C1; Densité:

: Numéro de catalogue:CM117046; Poids moléculaire:191; Point d'ébullition:; N° Mdl:MFCD00051907; Stockage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Alcohols; Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.

: Rilzabrutinib; Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These results were released at the 2024 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting and form the basis for the Phase 3 program which is on track to start in 2024. Rilzabrutinib is an oral, reversible, covalent BTK inhibitor that has the potential to be a first- or best-in-class treatment of a number of immune-mediated diseases.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.